Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD.

J Virol. 1994 Jul;68(7):4650-5.

2.
3.

Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.

Quinnan GV Jr, Yu XF, Lewis MG, Zhang PF, Sutter G, Silvera P, Dong M, Choudhary A, Sarkis PT, Bouma P, Zhang Z, Montefiori DC, Vancott TC, Broder CC.

J Virol. 2005 Mar;79(6):3358-69.

4.

Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.

Nehete PN, Chitta S, Hossain MM, Hill L, Bernacky BJ, Baze W, Arlinghaus RB, Sastry KJ.

Vaccine. 2001 Dec 12;20(5-6):813-25.

PMID:
11738745
5.

Cellular immune response to human immunodeficiency virus.

Norris PJ, Rosenberg ES.

AIDS. 2001 Feb;15 Suppl 2:S16-21. Review.

PMID:
11424972
6.

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.

Hel Z, Nacsa J, Tryniszewska E, Tsai WP, Parks RW, Montefiori DC, Felber BK, Tartaglia J, Pavlakis GN, Franchini G.

J Immunol. 2002 Nov 1;169(9):4778-87.

8.

Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.

Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, Johnston MN, Gao F, Walker BD, Rosenberg ES.

J Immunol. 2003 Apr 1;170(7):3906-14.

9.

Loss of T-cell cytotoxic responses in the course of HIV-1 infection.

Zerhouni B, Sanhadji K, Touraine JL.

Thymus. 1997;24(4):203-19.

PMID:
9493284
10.

Effects of adoptive immunotherapy with autologous CD8+ T lymphocytes on immunologic parameters: lymphocyte subsets and cytotoxic activity.

Torpey D 3rd, Huang XL, Armstrong J, Ho M, Whiteside T, McMahon D, Pazin G, Heberman R, Gupta P, Tripoli C, et al.

Clin Immunol Immunopathol. 1993 Sep;68(3):263-72.

PMID:
8370181
11.

Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1.

Deeks SG, Martin JN, Sinclair E, Harris J, Neilands TB, Maecker HT, Hagos E, Wrin T, Petropoulos CJ, Bredt B, McCune JM.

J Infect Dis. 2004 Jan 15;189(2):312-21. Epub 2004 Jan 7.

12.

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

AIDS Vaccine Evaluation Group 022 Protocol Team.

J Infect Dis. 2001 Feb 15;183(4):563-70. Epub 2001 Jan 18.

13.

Anti-HIV adaptive immunity: determinants for viral persistence.

Yamamoto H, Matano T.

Rev Med Virol. 2008 Sep-Oct;18(5):293-303. doi: 10.1002/rmv.577. Review.

PMID:
18416450
14.

Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients.

Legrand E, Pellegrin I, Neau D, Pellegrin JL, Ragnaud JM, Dupon M, Guillemain B, Fleury HJ.

AIDS Res Hum Retroviruses. 1997 Nov 1;13(16):1383-94.

PMID:
9359658
15.

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MB, Shaw GM.

Nat Med. 1997 Feb;3(2):205-11.

PMID:
9018240
16.

Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection.

Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, Miedema F.

J Infect Dis. 1998 Oct;178(4):1008-18.

17.

Human immunodeficiency virus type 1 (HIV-1)--and Epstein-Barr virus--specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1--infected persons.

Geretti AM, Dings ME, van Els CA, van Baalen CA, Wijnholds FJ, Borleffs JC, Osterhaus AD.

J Infect Dis. 1996 Jul;174(1):34-45.

19.

Kinetics of immune functions and virus replication during HIV-1 infection.

Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, Miedema F.

Immunol Lett. 1997 Jun 1;57(1-3):125-30.

PMID:
9232438
20.

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Mascola JR, Lewis MG, VanCott TC, Stiegler G, Katinger H, Seaman M, Beaudry K, Barouch DH, Korioth-Schmitz B, Krivulka G, Sambor A, Welcher B, Douek DC, Montefiori DC, Shiver JW, Poignard P, Burton DR, Letvin NL.

J Virol. 2003 Oct;77(19):10348-56.

Items per page

Supplemental Content

Write to the Help Desk